1. Home
  2. VFC vs PRAX Comparison

VFC vs PRAX Comparison

Compare VFC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V.F. Corporation

VFC

V.F. Corporation

HOLD

Current Price

$18.76

Market Cap

7.4B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$330.00

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VFC
PRAX
Founded
1899
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
9.6B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
VFC
PRAX
Price
$18.76
$330.00
Analyst Decision
Hold
Strong Buy
Analyst Count
17
15
Target Price
$17.56
$572.13
AVG Volume (30 Days)
5.8M
364.5K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
80.72
N/A
EPS
0.95
N/A
Revenue
$10,488,556,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
$6,395.88
P/E Ratio
$19.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.41
$26.70
52 Week High
$23.90
$354.87

Technical Indicators

Market Signals
Indicator
VFC
PRAX
Relative Strength Index (RSI) 40.04 53.52
Support Level $18.05 $290.36
Resistance Level $20.40 N/A
Average True Range (ATR) 0.90 18.34
MACD -0.25 -2.56
Stochastic Oscillator 24.76 57.24

Price Performance

Historical Comparison
VFC
PRAX

About VFC V.F. Corporation

VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: